AG-1295

Research use only, not for human use.

A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM.

A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM; inhibits PDGF-stimulated DNA synthesis with IC50 of 2.5 uM without affecting activity of EGFR; selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.Blood Cancer Discontinued.

Cell Viability Assay Cell Line:Rabbit conjunctival fibroblasts cells Concentration:1 μM, 10 μM, 100 μM Incubation Time:3 days Result:Inhibited rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB.

Animal Model:Sprague-Dawley rats (240-270 g)Dosage:12 mg/kg Administration:Intraperitoneal injection; daily; for 14 or 21 days Result:Attenuated interstitial fibrosis in rat kidney after unilateral obstruction.

NSC 380341 | Tyrphostin AG 1295

Angiogenesis

PDGFR

PDGFR

Cancer

Blood cancer

71897-07-9

234.3

C16H14N2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (213.40 mM)

CC1=C(C)C=C2N=CC(C3=CC=CC=C3)=NC2=C1

6,7-dimethyl-2-phenyl-quinoxaline

(-20℃)

With Ice Pack

≥ 2 years